Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 31, 2025
Reporting period
Not applicable
Filed with the SEC
Jan 5, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references dividend reinvestment
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001448074-26-000003
Filed / recorded
Jan 5, 2026, 10:00 PM UTC
Added to OQRO
Oct 2, 2026, 3:52 AM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
AbbVie Inc.
Issuer CIK
1551152
Ticker
ABBV
Reporting person
Robert J Alpern
Relationship
Director
Security
Stock Equivalent Units
Table
Derivative (Table II)
Transaction date
Dec 31, 2025
Transaction code
A
Shares / units
34
Price per share
$228.49
Acquired / disposed
Acquired (A)
Shares owned after
10,257
Ownership form
Direct
Amendment
No
Footnotes from the filing
Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Congress trade
Congress trade